| |
|
|
|
|
|
|
|||
|
Blood, 15 March 2005, Vol. 105, No. 6, pp. 2585-2593. Prepublished online as a Blood First Edition Paper on October 7, 2004; DOI 10.1182/blood-2002-11-3463.
Submitted December 12, 2002
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel * Corresponding author; email: yair.reisner{at}weizmann.ac.il.
Abstract
Previous studies suggest that cells within the CD34+ hematopoietic stem cell compartment are endowed with immune regulatory activity. Furthermore, it is possible to expand the human regulatory cells upon short-term culture of purified CD34+ cells with an early-acting cytokine cocktail. We now show that addition of anti-CD28, anti-CD2, IL-2, anti-IL-10, or IL-12 to the bulk MLR cannot reverse the inhibitory activity of the CD34+ cells, rulling out anergy based mechanisms, or mechanisms involving Th1-Th2 skewing. Furthermore, phenotyping of cells present after addition of CD34+ cells to the bulk MLR, ruled out potential induction of plasmacytoid dendritic precursors, known to be endowed with regulatory activity. In contrast, the inhibitory activity of CD34+ cells could be reversed by adding the caspase inhibitor BD-FMK to the bulk MLR, indicating a deletion based mechanism. The deletion can be inhibited by anti-TNF-
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||